This is a pre-blended stack of ipamorelin and CJC-1295 (no-DAC) that raises GH release, run in the community mostly for recovery, sleep quality, and anti-aging, with strong satisfaction reports for body composition. People most commonly dose 250 mcg a day, usually daily, though reported amounts range from 125 mcg to 2.5 mg. Sleep and dream effects are the most frequently reported experience, and they skew positive, though a minority describe disruption. There is no FDA-approved indication for the blend, so all human use is off-label or compounded.
Data last updated
Measured on 3 of 6 axes
Evidence shape
There is no published human clinical evidence for the Ipamorelin and CJC-1295 blend. While individual components of this combination appear in separate research contexts, no clinical trials exist for the specific blend itself. The absence of registered trials or published results means there is no data to support the efficacy or safety of this combination in human subjects.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
No animal or in-vitro support rows have been captured yet.
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How Ipamorelin / CJC-1295 Blend is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Most community users (~10 of 14) report an unscheduled dose around 300 mcg (range 150 mcg–2.5 mg), while a smaller group doses daily at 250 mcg; occasional use is three times daily at 125 mcg or weekly at 2 mg, with no cycling described.